download the onsite event guide - IBC Life Sciences

Plenary KeynotesMariner’s Ballroom8:00 Chairman’s Opening RemarksGünter Jagschies, Ph.D., Senior Director,Strategic Customer Relations, Bio TechnologiesR&D, GE Healthcare Life Sciences, Sweden8:15 Emerging Issues in the Regulationof BioproductsJeffrey C. Baker, Ph.D.Deputy Director, Office of BiotechnologyProducts, CDER, U.S. Food andDrug Administration9:00 CASE STUDY • UNPUBLISHED DATAManufacturing Antibodies of the Future– Utilizing a Low Cost, Low VolumeApproach to Help Solve the R&DProductivity ProblemJonathan Coffman, Ph.D.Director of Bioprocess Engineering,Boehringer Ingelheim9:45 Biosimilar: Challenges and the Path ForwardYongjick Kim, Ph.D.President, Manufacturing andTechnical Operations, Celltrion, Korea12:15 Concurrent TechnologyWorkshopsShoreline3M Technologies that Provide Single-Use,Flexible, Scalable Solutions for FiltrationLaura A. Brown, Marketing Manager, Zeta Plus ProductsDeb Bryan, Senior Project Engineer, 3M Purification, IncDriftwoodExploring the Unique Selectivity ofMixed-Mode Chromatography for ChallengingBiomolecule SeparationsXuemei He, Ph.D., Bio-Rad LaboratoriesMariner’s BallroomHigh Resolution, High Capacity and SaltTolerant Ion Exchange Resins for PolishChromatographyChristine Gebski, Head of the POROS ® ResinBusiness and Global Applications, Life TechnologiesSpeed Networking SessionWednesday, February 27th • 5:45 pm – 6:15 pmExhibit HallParticipants have pre-registered for this session,but there is still space if you are interested. If youwould like to join this session, you must visit theIBC Registration desk by 3:00 pm on Wednesday,February 27th. Take advantage of this opportunity tocreate many valuable relationships at BDP Week.(Pre-registration is required)12 www.IBCLifeSciences.com/BDPWeekWednesday, February 27, 2013ADC DevelopmentAntibody Development andand ProductionProduction – UpstreamDriftwoodFountain7:00 Registration and Coffee8:00 Plenary Keynotes: Jeffrey C. Baker, Ph.D., CDER, U.S. Food and Drug AdministrationJonathan Coffman, Ph.D., Boehringer Ingelheim Yongjick Kim, Ph.D., Celltrion, Korea (see details to the left)10:20 Networking Refreshment Break in Exhibit and Poster Hall11:10 Chairman’s RemarksOlivier Marcq, Ph.D., Senior Principal Scientist,Bioconjugates and Polytides, Biotherapeutics R&D,Pfizer Inc.Early Stage Process Development11:15 UNPUBLISHED DATA Novel Site-SpecificADCs – A Novel Amino Acid IncorporationTechnology in Mammalian CellsFeng Tian, Ph.D., Director, EuCode Technology,Ambrx Inc.11:45 UNPUBLISHED DATA ChemoenzymaticGeneration of Site-Specifically Modified ADCsDavid Rabuka, Ph.D., Chief Scientific Officer,Redwood Bioscience12:15Chairman’s RemarksJohn Joly, Ph.D., Director of Early Stage Cell Culture,Process Development, Genentech, a member of theRoche GroupIntegrating Cell Line Developmentwith DiscoveryUNPUBLISHED DATA Quality by Design Engineering– Use of Upfront Engineering, Diversity Analysisand Early Quality Attribute ScreeningMargaret Karow, Ph.D., Executive Director,Biologics, Amgen Inc.Quality by Design during Cell LineDevelopmentSusan Dana Jones, Ph.D., Vice President and SeniorConsultant, BioProcess Technology Consultants, Inc.Technology Workshops Sponsored by (Shoreline) (Driftwood)(Mariner’s Ballroom)(see details to the left)12:45 Networking Luncheon in Exhibit and Poster HallEarly Stage Process Development(continued)2:00 Concept to Clinic in 365 Days; Design andProduction of Optimized ADCsTrevor Hallam, Ph.D., Chief Scientific Officer,Sutro Biopharma, Inc.2:30 Antibody-Drug Conjugates: TechnologyAdvances in Linkers and Cytotoxic AgentsRavi J. Chari, Ph.D., Executive Director, Chemistryand Biochemistry, ImmunoGen, Inc.3:00 UNPUBLISHED DATA Next Generation ADCs:Higher Drug Loading, Alternative Payloadsand Alternative Targeting MoietiesTimothy B. Lowinger, Ph.D., Chief ScientificOfficer, Mersana TherapeuticsHost Cell Genomics and ProductionCell MetabolismUNPUBLISHED DATA Improving Productivity byBetter Understanding Cell Line MetabolismSohye Kang, Ph.D., Principal Scientist, ProductAttribute Sciences, Amgen Inc.CASE STUDY • UNPUBLISHED DATA Using SyntheticBiology, LEAP and Computational Modeling inan Integrated Platform for Accelerated HumanmAb Discovery and DevelopmentFred Koller, Ph.D., Vice President, ProteinProduction Division, Intrexon Institute forBiomolecular ResearchCASE STUDY • UNPUBLISHED DATA IndustrialProcess Development, A Case Study inEfficiency and AutomationMichael Isaacs, Scientist, Automation andDevelopment, Broadley James Corp.3:30 Networking Refreshment Break in Exhibit and Poster Hall4:15Thought Leadership ForumReducing the Risk of a Contamination EventDue to Raw Materials – Part IIRapid Process Development –Balancing Speed and RiskCASE STUDY • UNPUBLISHED DATA How QuicklyCan You Generate a Stable Cell Line?Rubai Ding, Ph.D., Senior Scientist,Bayer HealthCareSponsored by:4:45 UNPUBLISHED DATA Higher Titer Clones in LessModerator:Time: An Optimized Work Flow for RecombinantBarbara Potts, Ph.D., Senior Consultant, CHO Cell Line DevelopmentPotts and Nelson Consulting, LLCChristine DeMaria, Ph.D., Associate Director, TherapeuticProtein Expression, Genzyme, A Sanofi Company5:15 Networking Wine and Cheese Reception with Exhibit and Poster Viewing